Enveric Biosciences Inc (ENVB) News

Interesting chart forming

envb.......................................https://stockcharts.com/h-sc/ui?s=envb&p=W&b=5&g=0&id=p86431144783

Close enough to warrant price of $4.15

News
Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent
New patent for mescaline derivative compounds broadens Enveric’s potential to develop neuroplastogen therapeutics for addiction and neuropsychiatric disorders

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that the United States Patent and Trademark Office issued U.S. Patent No. 12,195,439 (the ‘439 patent) on January 14, 2025.

Entitled “Cl-Substituted Isopropylamine Fused Heterocyclic Mescaline Derivatives,” the ‘439 patent is the first Enveric patent to be issued for its new EVM401 Series. Further development of the EVM401 Series of compounds is intended to broaden Enveric’s pipeline with additional non-hallucinogenic molecules and strengthen its ability to target addiction and neuropsychiatric disorders for patients with limited options. Preliminary testing of the EVM401 series of compounds and their metabolites has demonstrated unique patterns of brain receptor modulation emerging from the compounds’ distinct molecular structures.

Specifically, preliminary data suggest that these mescaline derivative compounds may interact with a variety of important neurological receptors, including the a2A adrenergic receptor (ADRA2A), the 5-HT2C receptor, and the dopamine transporter (DAT). ADRA2A agonists are known to help manage the symptoms of opioid withdrawal and treat conditions such as ADHD, while the 5-HT2C receptor is an emerging therapeutic target in the treatment of neuropsychiatric diseases, including substance use disorders, anxiety and depression. Notably, DAT is also an important target in the treatment of substance use disorders.

“Enveric is pleased to have secured this foundational U.S. patent and is excited for the potential of the EVM401 Series,” said Dr. Joseph Tucker, CEO of Enveric. “While our corporate and development strategy is focused squarely on preparing for the Investigational New Drug application for EB-003, we continue to explore opportunities to expand our development pipeline in order to build shareholder value.”

About Enveric Biosciences

Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Leveraging its unique discovery and development platform, the Psybrary™, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, Enveric seeks to develop a robust intellectual property portfolio of novel drug candidates. Enveric’s lead molecule, EB-003, is intended to offer a first-in-class, new approach to the treatment of difficult-to-address mental health disorders, mediated by the promotion of neuroplasticity and without also inducing hallucinations in the patient. Enveric is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing all other novel, patented Psybrary™ drug candidates to third-party licensees advancing non-competitive market strategies for patient care. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, AB Canada. For more information, please visit www.enveric.com.

Forward-Looking Statements

This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans,” “expects” or “does not expect,” “proposes,” “budgets,” “explores,” “schedules,” “seeks,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: successfully outlicense patented PsybraryTM drug candidates to third-party licensees; negotiate and finalize definitive agreements based on any of its out-licensing term sheets and for licensees to perform pursuant to the terms thereof; finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric’s products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively.

A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the Securities and Exchange Commission, including Enveric’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

https://cts.businesswire.com/ct/CT?id=bwnews&sty=20250225442223r1&sid=acqr8&distro=nx&lang=en

View source version on businesswire.com: https://www.businesswire.com/news/home/20250225442223/en/

Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
dirish@tiberend.com

Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
(646) 577-8520
cmcdonald@tiberend.com

Source: Enveric Biosciences

https://www.otcmarkets.com/stock/ENVB/news/story?e&id=3153401[color=red][/color]

Offering 1.2m shares at $4.15..

We are offering up to 1,204,819 shares of common stock, together with Series A warrants to purchase up to 1,204,819 shares of common stock, which we refer

 to as the “Series A warrants,” and Series B warrants to purchase up to 1,204,819 shares of common stock, which we refer to as the “Series B warrants,” pursuant to this prospectus. The assumed combined public offering price for each share of common stock, together with each Series A warrant and Series B warrant to purchase one share of common stock, is $4.15, https://www.sec.gov/Archives/edgar/data/890821/000149315225004213/forms-1a.htm

15% ownership in company they will be hitting the sell sell button sometime today.. https://www.sec.gov/Archives/edgar/data/890821/000121390025010594/xslSCHEDULE_13G_X01/primary_doc.xml

After and premarket pump of patents $2.84 + 140%

ENVB anew 52/week low

envb.....................................https://stockcharts.com/h-sc/ui?s=envb&p=W&b=5&g=0&id=p86431144783

DILUTE INTO NEWS.....WELCOME TO THE SUB PENNY NASDAQ DILUTION PROGRAMS

Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003

ENVB...........................https://stockcharts.com/h-sc/ui?s=ENVB&p=W&b=5&g=0&id=p86431144783

ENVB new 52 week low

Mighty fluffy press release

Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease

ENVB under $2

ENVB.........................................https://stockcharts.com/h-sc/ui?s=ENVB&p=W&b=5&g=0&id=p86431144783

ENVB: The Pro's are now workin' on their THIRD-NICE-FLIP behind this (easy money) puppy today!!! (I.e., one 100%-profit flip in the Pre-M, & now TWO circa 25-to-30%-profit flips in the Open-M!!! Yet STUPID traders cry about "Wash Trades". L.M.M.F.A.O.!!!!!)

ENVB: Heck, "Wash-Trades" keep those PROFITS nice & CLEAN!!!!

Wash trade du jour

ENVB: I'm buyin' latte's for everyone later today, up on the MOON!!!

ENVB: 3-bagger from here, whether anybody likes it or not!! (Just the way it goes, these days!!)

Nasty trap

Short

The term sheets further provide that, Enveric could be eligible to receive future development and sales milestone payments and execution fees for the three licenses, which in total could add up to $200 million, assuming certain conditions are met, including receiving approval for the investigational new drug (IND) applications and completing Phases I through III testing of the licensed products. Royalty rates on each of the three licenses could range from 2.5% up to 10% on future sales, depending on meeting certain sales criteria. The compound classes under the term sheets come from two of the seven portfolios of preclinical molecules that Enveric recently unveiled as available for out-licensing. Numerous molecules and classes remain available for additional out-licensing opportunities.

“Patients living with serious mental health conditions have seen insufficient innovation for far too long, and we are excited for the opportunity to progress several of the novel compounds generated using our drug discovery engine,” said Joseph Tucker, Ph.D., Director and CEO of Enveric. “We look forward to working with our partner, and we are confident in their leadership and capabilities to work on further developing these drug candidates to advance treatment options for patients. Ultimately, we believe the definitive licensing agreements, once negotiated and finalized, could represent an excellent potential source of revenue for Enveric, and could demonstrate the value creation from Enveric’s discovery capabilities and proprietary PsyAI™ and Psybrary™ platforms, which have already generated an impressive library of compounds targeting a variety of CNS disorders.”

ENVB.........................................https://stockcharts.com/h-sc/ui?s=ENVB&p=W&b=5&g=0&id=p86431144783

Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property

What's the patent application number?

IG

4.96 to 3 blink of any eye

7.52 easy

$4-$5.75. Done for the day. Wooo

Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug

Nice flipper

Ok it cooled off
Five dollar run

Now a Rug Pooool candidate lol... Now it's too dangerous... It can run 4+ but it can dump too as seen from 4.20s to 3.20s in all of 15 seconds

Another rip or another dump, only the devil knows

Good call. Ran to 4.20s and dumped to 3.20s

I’m out

https://stockcharts.com/h-sc/ui?s=envb&p=D&yr=0&mn=6&dy=0&id=p38090673899

https://www.barchart.com/stocks/quotes/envb/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=SYSX&grid=1&height=210&studyheight=100

https://www.barchart.com/stocks/quotes/envb/opinion

Open gap at $1.52

There's another pullback

Ooooooops!! (iHub posting error, glitch, etc.).

ENVB: I'm workin' on an ANSWER to your question right now, Sir. (See my 'Chart' on this, below.)

WALL @ 3.50 JUST TAKEN OUT

Anyone smell a bait and pull? Lol or do we forsee $5- 6

ENVB: See ya-all up on the MOON later, Folks!!

Same. I expect pullbacks and runs if the volume stays consistent.. which means mass flipping

Watching

This could run 5 - 6 today.

Sell down now

Enveric Biosciences Receives Notice of Allowance from USPTO for Novel Prodrug of Psilocin